STOCK TITAN

Opko Health Inc. - $OPK STOCK NEWS

Welcome to our dedicated page for Opko Health news (Ticker: $OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opko Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opko Health's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
conferences
Opko Health Inc.

Nasdaq:OPK

OPK Rankings

OPK Stock Data

906.09M
331.18M
52.41%
25.07%
13.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MIAMI

About OPK

opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-­4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-­1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig